Last reviewed · How we verify
Carbon-14 BIA 28-6156
Carbon-14 BIA 28-6156 is a Small molecule drug developed by Bial R&D Investments, S.A.. It is currently in Phase 1 development.
At a glance
| Generic name | Carbon-14 BIA 28-6156 |
|---|---|
| Sponsor | Bial R&D Investments, S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbon-14 BIA 28-6156 CI brief — competitive landscape report
- Carbon-14 BIA 28-6156 updates RSS · CI watch RSS
- Bial R&D Investments, S.A. portfolio CI
Frequently asked questions about Carbon-14 BIA 28-6156
What is Carbon-14 BIA 28-6156?
Carbon-14 BIA 28-6156 is a Small molecule drug developed by Bial R&D Investments, S.A..
Who makes Carbon-14 BIA 28-6156?
Carbon-14 BIA 28-6156 is developed by Bial R&D Investments, S.A. (see full Bial R&D Investments, S.A. pipeline at /company/bial-r-d-investments-s-a).
What development phase is Carbon-14 BIA 28-6156 in?
Carbon-14 BIA 28-6156 is in Phase 1.
Related
- Manufacturer: Bial R&D Investments, S.A. — full pipeline
- Compare: Carbon-14 BIA 28-6156 vs similar drugs
- Pricing: Carbon-14 BIA 28-6156 cost, discount & access